Stomach Neoplasm Clinical Trial
Official title:
The Gastric HormonE BioMarkers of Preneoplastic Lesions (GEM) Study
The goal of the study is to understand whether blood levels of hormones produced or metabolized in the stomach reflect the health of the stomach lining. Specifically the study will determine whether the concentration of ghrelin, gastrin, pepsinogens and vitamin B12 reflect the condition of the stomach lining. Hormone concentrations for people with normal/mild gastritis will be compared to people with long-term inflammation of the stomach (chronic atrophic gastritis), and people with pre-cancerous cellular changes (intestinal metaplasia).
Previously published promising data show that blood levels of ghrelin, gastrin, vitamin B12 and pepsinogen are each associated with risk of developing stomach cancer. These studies used blood bank samples and looked at risk of cancer many decades later. This study was designed to explore whether these markers could be useful in a clinical setting for early detection of stomach cancer. The study will recruit at 3 sites over 1 year identifying patients with chronic atrophic gastritis and intestinal metaplasia and those with mild gastritis. Only the patient data which is absolutely necessary for analysis will be collected, to include basic demographics, relevant medical history and medications. These data will be used to analytically account for alternative explanations for variation in blood measurements of ghrelin, gastrin, pepsinogen and vitamin B12. A one-time venous blood sample will be collected to enable measurement of the markers of interest. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03313700 -
Clinical Outcomes of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer
|
N/A | |
| Recruiting |
NCT05645198 -
The Effect of Carboxymetyl Starch (Oozfix) on Preventing Postoperative Complication After Gastrectomy
|
Phase 4 | |
| Completed |
NCT03549494 -
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
|
Phase 2 | |
| Completed |
NCT00144378 -
Irinotecan Versus Only Best Supportive Care for Gastric Cancer
|
Phase 3 | |
| Completed |
NCT00935779 -
Ultra Structure Of Peritoneum At Electronic Microscopy In Control Subjects And Patients With Gastric Cancer
|
N/A | |
| Completed |
NCT00290966 -
Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03348150 -
Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.
|
Phase 3 | |
| Recruiting |
NCT02969122 -
Treatment Strategy for Stage IV Gastric Cancer With Positive Peritoneal Cytology as the Only Non-curable Factor
|
N/A | |
| Completed |
NCT01482299 -
RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression
|
Phase 2 | |
| Active, not recruiting |
NCT03760822 -
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
|
Phase 2 | |
| Recruiting |
NCT00509964 -
Second-Line Irinotecan vs. ILF for AGC
|
Phase 2 | |
| Completed |
NCT04889859 -
Impact of Biliopancreatic Limb Length on Diabetes Following Distal Gastrectomy
|
N/A | |
| Completed |
NCT03071237 -
The Origin of Infrapyloric Artery
|
||
| Recruiting |
NCT05184803 -
A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT05714878 -
Multimodal Prehabilitation for Resectable Gastric Cancer
|
N/A | |
| Completed |
NCT00142038 -
Docetaxel and Capecitabine in Advanced Gastric Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT04056260 -
ICG-NIR Guided Lymph Node Dissection in Gastric Cancer
|
N/A | |
| Recruiting |
NCT03065257 -
Endoscopic Resection Multicenter Registry
|
N/A | |
| Recruiting |
NCT04744649 -
Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial
|
Phase 2 | |
| Recruiting |
NCT05640609 -
Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer
|
Phase 1/Phase 2 |